loading
Neumora Therapeutics Inc stock is traded at $0.7783, with a volume of 370.33K. It is up +5.34% in the last 24 hours and up +0.85% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$0.7431
Open:
$0.747
24h Volume:
370.33K
Relative Volume:
0.37
Market Cap:
$125.66M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.3071
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
+9.42%
1M Performance:
+0.85%
6M Performance:
-91.99%
1Y Performance:
-92.17%
1-Day Range:
Value
$0.7391
$0.7963
1-Week Range:
Value
$0.69
$0.7963
52-Week Range:
Value
$0.611
$17.19

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name
Name
Neumora Therapeutics Inc
Name
Phone
(857) 760-0900
Name
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Name
Employee
103
Name
Twitter
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NMRA
Neumora Therapeutics Inc
0.7769 113.13M 0 -274.18M -198.33M -2.5346
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.50 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.81 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.24 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
488.50 65.13B 14.09B 4.50B 2.96B 39.28

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-02-25 Downgrade BofA Securities Buy → Underperform
Mar-10-25 Downgrade William Blair Outperform → Mkt Perform
Mar-07-25 Downgrade Guggenheim Buy → Neutral
Mar-07-25 Downgrade Stifel Buy → Hold
Jan-02-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-05-24 Downgrade JP Morgan Overweight → Neutral
Oct-01-24 Initiated H.C. Wainwright Buy
Jul-22-24 Initiated Needham Buy
Jul-08-24 Initiated Mizuho Outperform
Dec-12-23 Initiated Deutsche Bank Hold
Oct-10-23 Initiated BofA Securities Buy
Oct-10-23 Initiated Guggenheim Buy
Oct-10-23 Initiated JP Morgan Overweight
Oct-10-23 Initiated RBC Capital Mkts Outperform
Oct-10-23 Initiated Stifel Buy
Oct-10-23 Initiated William Blair Outperform
View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

pulisher
Jun 01, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Ameriprise Financial Inc. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Jun 01, 2025
pulisher
May 30, 2025

Neumora Therapeutics Holds Annual Stockholders Meeting - TipRanks

May 30, 2025
pulisher
May 29, 2025

BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

May 29, 2025
pulisher
May 28, 2025

Deutsche Bank AG Has $775,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

May 28, 2025
pulisher
May 27, 2025

Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm - GlobeNewswire Inc.

May 27, 2025
pulisher
May 25, 2025

26,500 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Bought by Janus Henderson Group PLC - Defense World

May 25, 2025
pulisher
May 22, 2025

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development - Investing.com India

May 22, 2025
pulisher
May 22, 2025

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st

May 22, 2025
pulisher
May 21, 2025

Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

May 21, 2025
pulisher
May 20, 2025

Price T Rowe Associates Inc. MD Cuts Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

May 20, 2025
pulisher
May 19, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp - Defense World

May 19, 2025
pulisher
May 18, 2025

Orbimed Advisors LLC Has $8.53 Million Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

May 18, 2025
pulisher
May 18, 2025

Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

May 18, 2025
pulisher
May 17, 2025

HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings - MarketBeat

May 17, 2025
pulisher
May 17, 2025

Neumora Therapeutics faces Nasdaq delisting risk - Investing.com Australia

May 17, 2025
pulisher
May 17, 2025

The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

May 17, 2025
pulisher
May 17, 2025

Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat

May 17, 2025
pulisher
May 16, 2025

Neumora Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Neumora Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks

May 16, 2025
pulisher
May 16, 2025

Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

What is HC Wainwright’s Forecast for NMRA Q2 Earnings? - Defense World

May 16, 2025
pulisher
May 16, 2025

William Blair Analysts Increase Earnings Estimates for NMRA - Defense World

May 16, 2025
pulisher
May 15, 2025

Neumora Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 15, 2025
pulisher
May 14, 2025

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - The Malaysian Reserve

May 14, 2025
pulisher
May 13, 2025

Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating - TipRanks

May 13, 2025
pulisher
May 13, 2025

Neumora Therapeutics Venture Debt Facility - Leerink Partners

May 13, 2025
pulisher
May 13, 2025

Neumora Therapeutics (NMRA) Retains Buy Rating with Stable Price Target | NMRA Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements - TipRanks

May 13, 2025
pulisher
May 13, 2025

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Neumora Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

Earnings call transcript: Neumora Therapeutics Q1 2025 Sees Net Loss, Stock Rises - Investing.com

May 12, 2025
pulisher
May 12, 2025

Neumora Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Transcript : Neumora Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com

May 12, 2025
pulisher
May 11, 2025

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely? - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire

May 11, 2025
pulisher
May 10, 2025

Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister

May 09, 2025
pulisher
May 09, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat

May 09, 2025
pulisher
May 08, 2025

Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

May 08, 2025
pulisher
May 07, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World

May 07, 2025
pulisher
May 06, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

May 06, 2025
pulisher
May 05, 2025

Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat

May 05, 2025
pulisher
May 04, 2025

Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

May 04, 2025
pulisher
May 02, 2025

NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com

May 02, 2025
pulisher
May 02, 2025

Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News

May 02, 2025
pulisher
May 02, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World

May 02, 2025

Neumora Therapeutics Inc Stock (NMRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Neumora Therapeutics Inc Stock (NMRA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BERNS PAUL L
See Remarks
Feb 18 '25
Sale
1.69
13,871
23,468
7,405,004
Milligan Michael Lee
See Remarks
Feb 18 '25
Sale
1.69
1,978
3,351
22,470
Aurora Daljit Singh
Chief Strategy Officer
Feb 18 '25
Sale
1.68
8,565
14,347
88,935
Lenz Robert A.
Head of R&D
Feb 18 '25
Sale
1.67
5,614
9,383
309,092
Pinto Joshua
President
Feb 18 '25
Sale
1.67
8,048
13,477
76,952
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price up icon 0.56%
Cap:     |  Volume (24h):